April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Dioptin™: A novel pharmaceutical formulation for restoration of accommodation in presbyopes
Author Affiliations & Notes
  • Kathryn S Crawford
    PharmOcu, Andover, MA
    Research, Encore Vision, Fort Worth, TX
  • William H Garner
    Research, Encore Vision, Fort Worth, TX
  • William Burns
    Research, Encore Vision, Fort Worth, TX
  • Footnotes
    Commercial Relationships Kathryn Crawford, Encore Vision (C), Encore Vision (I); William Garner, Encore Vision (C), Encore Vision (F), Encore Vision (I), Encore Vision (P); William Burns, Encore Vision (E), Encore Vision (I)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3765. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kathryn S Crawford, William H Garner, William Burns; Dioptin™: A novel pharmaceutical formulation for restoration of accommodation in presbyopes. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3765.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Dioptin™ ophthalmic formulation for presbyopia is under development with plans to enter clinical trials in 2014. Dioptin™ contains the proprietary active pharmaceutical ingredient, EV06 (lipoic acid choline ester), which is a prodrug of lipoic acid (LA), enhancing LA corneal permeability. Studies were conducted to establish drug tolerability and safety when applied topically in ophthalmic formulation.

Methods: Screening studies were conducted to determine the highest tolerated concentration when applied topically to rabbit eyes, in conjunction with bioanalysis of corneal, aqueous humor, and lens concentrations of EV06 and its metabolites. In a GLP rabbit study, animals were treated with topical 0, 1, 3 or 4% Dioptin solution three times daily for 90 consecutive days. Slit-lamp exams and fundoscopy were performed at pre-dose baseline and after 1, 30, and 90 days of dosing. Daily clinical observations, food consumption, body weights, clinical pathology, and toxicokinetics were performed. Full necropsy and ocular histopathology were also conducted.

Results: Dioptin™ ophthalmic formulations were well tolerated in rabbit eyes. No dose-related ocular signs of toxicity were observed at any timepoint in the GLP study. Ophthalmic exams were normal, with the exception of mild (1+) conjunctival congestion and (1+) discharge observed in some of animals dosed with 3% or 4% Dioptin™ on the first day of dosing, which persisted throughout the dosing period, but did not worsen. No systemic effects or adverse events were reported. Plasma levels of EV06 were at or below the limits of detection, indicating rapid metabolism.

Conclusions: Dioptin™ is a promising new treatment for presbyopia, with the potential to restore several diopters of accommodation. In preclinical studies, EV06 has been shown to be effective at increasing lens elasticity through reduction of lens protein disulfides. The ophthalmic formulation is non-irritating, and systemic and ocular safety have been demonstrated in a 90 day GLP ocular toxicology study at topical doses up to 4% three times daily.

Keywords: 404 accommodation • 653 presbyopia  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.